Introduction

Reproduction is made possible by fertilisation of the ovum generated each month by a physiologically normal female by sperm contributed by her partner. Although in vitro fertilization (IVF) is feasible, in most cases this process occurs by an enjoyable intercourse. The fertilized egg develops to the blastocyst stage (whether after in vitro or in vivo fertilization) when it is ready for implantation onto a receptive endometrium which leads to pregnancy. In this process, human chorionic gonadotropin (hCG), a hormone produced by the growing embryo plays a critical role. We developed a vaccine against hCG, which has the ability to generate antibodies competent to intercept this process and thereby prevent the onset of pregnancy. This article will briefly review this work and report its current status.

The choice of hCG as a ‘target’ was based on two considerations:

a) The fact that this molecule is not produced normally by any organ of a healthy non-pregnant female, and thus the antibodies against it would not produce side-effects.

b) That hCG plays a key role in implantation and hence antibodies competent to neutralize its bioactivity would block the key step leading to pregnancy without affecting the normal female functions of ovulation, production of hormones and periodicity of menstruation.

Design of the Vaccine

hCG is composed of 2 subunits, alpha and beta linked to each other non-covalently [1]. Figure 1 shows the structure of these hormonal subunits.

Alpha subunit of hCG is common to 3 other pituitary hormones, namely FSH, LH and TSH. It is the beta subunit of each hormone that gives them the individual character. Hence we decided to employ β subunit of hCG as antigen in the vaccine. The beta subunit however is a “self” molecule and the body would not produce antibodies against it. It was made immunogenic by linking it to a carrier tetanus toxoid (TT). TT is used world-wide for immunization to prevent tetanus. It is a cheap vaccine, available in plenty commercially. βhCG-TT conjugate did generate antibodies against both hCG and tetanus, not only in experimental animals but also in women (Figure 2). The initial trial was conducted in 4 women. They had completed their families and got themselves tubectomized to prevent further pregnancies.
Antibodies were generated against both hCG and tetanus. Injection of a load dose of hCG bound to anti-hCG antibodies, bringing down their titres without influencing antibodies against tetanus. The anti-hCG titres returned to the previous level in course of time. The anti-tetanus antibodies remained at the same level indicating that the vaccine generated independent antibodies against both hCG and tetanus. Figure 3 shows the kinetics of anti-hCG antibodies in 2 subjects enrolled in this study. Immunization with hCGβ-TT vaccine was fully safe and devoid of any side-effects [2,3]. In all 4 women, the antibody response was reversible and the antibody titres declined to zero level in course of time.

**Enhancement of Immunogenicity**

While linkage of hCGβ to a carrier (TT) did make it immunogenic in women, the titres of antibodies induced were low and insufficient to neutralize the hCG that is formed at the early stages of pregnancy. Strong and oily adjuvants, if used, would entail side-effects deterring potential recipients to get vaccinated. One had to enhance the intrinsic immunogenicity of the vaccine employing permissible, easily tolerated adjuvants. We considered associating the β subunit of hCG with α subunit of ovine LH, which being a non-self molecule is expected to be intrinsically immunogenic in humans. The ability of α and β subunits to associate with each other non-covalently is preserved across the species. The hetero-species-dimer (HSD) of hCGβ with αoLH, was indeed more immunogenic and generated better neutralizing hCG antibodies. Table 1 summarises some of the findings. The procedures followed are reported elsewhere [4].

The next obvious question was whether this vaccine indeed prevented pregnancy in fertile women. For this Phase II trials were necessary which were conducted after obtaining permission of the Drugs Controller General of India (DCGI) and Institutional Ethics Committees.

**Efficacy of the vaccine to prevent pregnancy**

Phase II clinical trials were conducted in three centres in India: the All India Institute of Medical Sciences New Delhi, Postgraduate Institute of Medical Education & Research Chandigarh and Safdarjung Hospital New Delhi. Women of reproductive age with 2 living children who had active marital life with frequent intercourses were enrolled for the trial by written consent. All of them had regular menstrual cycles. Luteal phase Progesterone terminations indicated that they were ovulating regularly. The enrolled women were immunized with 300μg of HSD-TT vaccine. A course of 3
primary injections at 15 or 30 day interval was necessary to lead
to the induction of antibodies. Thereafter booster injections were
given as and when the antibodies declined. A putative threshold of
antibodies at and above 50ng/ml bio neutralization capacity of hCG
was fixed to see whether at these antibody titres and above, she
was protected from becoming pregnant.

A total of 148 women were enrolled for this trial. While all of
them generated antibodies against hCG after vaccination, however
110 of them had titres above the presumed protective threshold of
50ng/ml for at least 3 months or longer. Figure 4 shows the findings
in 4 women [5].

**Figure 4:** Anti-hCG response to the HSD vaccine in 4 sexually active women of proven fertility. MRG 30 year old and TRW 23 year
old had 2 children each; HJN 32yr & SVN 29 year old had 2 children each and 1 elective termination of pregnancy. All of them
remained protected from becoming pregnant over 26-32 cycles, at top edge are represented the menstrual events which remained
regular, solid lines denote the period over which they were exposed to pregnancy. Arrows indicate the day on which vaccine was
given. Booster injections were given to keep antibody titres above 50ng/ml [5].

The vaccine was highly effective in preventing pregnancy. Only one pregnancy occurred in 1224 cycles. All women kept
ovulating normally and had regular menstrual cycles. Eight women
were protected for 30 cycles without becoming pregnant, nine
were protected over 24-29 cycles, 15 for 12-17 cycles and 21 for
6-11 cycles. Thus the vaccine had high efficacy. What is more,
contraception was achieved without derangement of menstrual
regularity and hormonal profiles. In this respect, it was a unique
vaccine for Birth Control.

**Reversibility and regain of fertility**

While antibodies declined in course of time to near zero level in
all women in the absence of boosters, one had to determine whether
previously immunized women regain fertility. Luckily 4 women in
the cohort undergoing the trial, desired to have another child, and
did not take booster injections. All 4 of them conceived and carried
to term their pregnancy. Figure 5 gives the antibody response in
one of these women, who remained protected for nearly one year
after 3 primary injections and a booster. She conceived in the first
cycle, when her antibody titres declined below 20ng/ml. She gave
birth to a normal child.

**Figure 5:** Regain of fertility on decline of antibodies. A
30-year-old subject (STS), with two gravidae and one
elective abortion (P2+1), on immunization with the vaccine,
remained protected from pregnancy for 12 cycles. In the
absence of a booster injection, antibody titers declined
and she became pregnant in the cycle starting on day 417.
The extrapolated antibody titers at mid cycle in the fertile
month, shown by the dotted line, were <5ng/ml. Arrows
indicate the day on which vaccine was given [5].
Normalcy of children born to women on decline of antibody titres

Prof. Meharban Singh at the All India Institute of Medical Sciences, New Delhi, examined thoroughly the 4 children born to women previously immunized with the HSD-TT vaccine. Their developmental landmarks and cognitive abilities were normal and comparable to their siblings [6].

To sum up, the vaccine linking hCGβ subunit to a carrier engendering antibodies against hCG prevented unwanted pregnancy in women without blocking their ovulation and derangement of menstrual regularity. The effect of the vaccine was fully reversible. On decline of antibodies in the absence of a booster, women conceive after decline of antibodies to below 30ng/ml. The progeny born is normal as per the developmental landmarks and cognitive abilities of their siblings.

Time Gap and revival of the vaccine

I retired from the Directorship of the National Institute of Immunology (NII), New Delhi, in 1994. My successor requested me to leave the vaccine at the Institute which I created and of which I was the Founder Director. How could I refuse it? Nothing was done till 2006, when an Indo-US Committee on Contraception Research contacted me to revive the vaccine. I decided to make a genetically engineered recombinant vaccine, which could be amenable to industrial scale production. The β-subunit of hCG was linked to B subunit of heat-labile enterotoxin (LTB) of Escherichia coli as carrier, and expressed as recombinant protein in yeast Pichiapastoris.

Figure 6: Enhancement of antibody response to hCGβ-LTB vaccine in Balb/c mice by MIP. Mice were immunized intra-muscularly with 2µg of the vaccine adsorbed on alum with or without MIP. Primary immunization consisted of 3 injections given at fortnightly intervals followed by a booster on day 60 or 120. The symbols represent the titres in a given mouse. Bars give the geometrical Means [7].

Figure 7: Effect of immunization with heat-killed MIP or live BCG on development of pulmonary lesions in C3H, CBA (Panel A) and in Balb/c, C57BL/6 (Panel B) strains of mice. Animals were immunized either with 107 heat-killed MIPs.c. or 104 live BCG i.v. Four weeks later, the animals were challenged with 107M. tuberculosis H37Rv.i.v. Four weeks post challenge, the animals were killed and visible lesions in the lungs were recorded. The data plotted are the mean of results obtained from three sets of experiments with MIP and two sets of experiments with BCG, with n=7-10 animals per group. The data for the non-immunized group of animals are also presented [10].

Approvals of hCGβ-LTB vaccine

All genetically engineered products have to receive the approval of the National level Review Committee on Genetic Manipulation (RCGM) before these are considered for human use. The committee desired extensive toxicology studies to be carried out on this vaccine by a GLP company employing International Protocols. Pre-clinical toxicology studies were carried out in 2 species of rodents by M/s Bioneeds at their GLP Facility in Bangalore India. Vaccine was fully safe by all criteria and also free of mutagenicity with no sensitization of skin. Safety and immunogenicity studies on the hCG β-LTB vaccine adsorbed on alhydrogel was immunogenic and generated bioneutralizing anti-hCG antibodies in Balb C mice. Its immunogenicity was considerably enhanced by inclusion of an adjuvant, heat-killed Mycobacterium indicus pranii (MIP) (Figure 6) [7]. MIP is a non-pathogenic atypical mycobacteria, which I had developed as an immunoprophylactic cum immune-therapeutic vaccine against leprosy [8]. It is approved by the DCGI and USFDA. Besides leprosy, it is effective as adjunct to standard drugs in treatment of Category II “Difficult to treat” tuberculosis [9]. MIP is superior to BCG, as it is active in both live and heat-killed form. Unlike BCG, it has no genetic restriction (Figure 7).
recombinant hCGβ-LTB vaccine were also conducted in a subhuman primate species, the marmosets, at the National Institute of Research in Reproduction (NIRRH), Mumbai. Vaccine was found fully safe. Marmosets offered an additional opportunity to test the efficacy of antibodies in preventing pregnancy. 8/9 immunized marmosets were protected from becoming pregnant on co-habitation with fertile males, whereas all non-immunized marmosets in the control group became pregnant. On the basis of these findings, the vaccine received approval of RCGM, who recommended to DCGI to grant approval for going back to human trials.

**Current Status**

The approval of DCGI for conducting Phase I/II safety and efficacy trials has been received. The trial will be conducted under the aegis of the Indian Council of Medical Research. Also technology for making the vaccine has been transferred to a Biotech Company, who will make the vaccine under GMP conditions and supply it free of charge for the trial.

**Acknowledgement**

The work received research grants from the Department of Biotechnology, Govt of India and the Indian Council of Medical Research, New Delhi.

**References**